Imagine you're testing a new type of organic fertilizer on a batch of tomato plants. You split them into two groups: one gets the new formula, and the other gets the standard stuff. Now, if you only measure the plants that survived until the end of the season, you're cheating—maybe the new fertilizer was so potent it actually killed the weakest plants. To be honest about the results, you have to account for every single plant you started with, regardless of whether it made it to the finish line. That's the heart of clinical trial analysis.

In R, we map this logic directly to how we handle patient data. The "new fertilizer" is your Treatment Arm, the "standard stuff" is your Control Arm, and the "growth measure" is your Primary Endpoint. The "dead plants" represent Patient Attrition. If we just ignore the people who dropped out of a study, we introduce "attrition bias," and the FDA (or any serious reviewer) will tear the analysis apart.

Handling the Treatment Effect with Linear Models

For this lesson, let's look at a trial for a hypothetical drug, "Hypotens-X," designed to lower systolic blood pressure (SBP). We aren't just looking for a number; we're looking for the difference in means between the treatment group and the placebo group, adjusted for their starting blood pressure.

library(tidyverse)
library(broom)

# Simulating a small clinical dataset
set.seed(42)
trial_data <- tibble(
  patient_id = 1:100,
  group = sample(c("Treatment", "Placebo"), 100, replace = TRUE),
  baseline_sbp = rnorm(100, 150, 10),
  final_sbp = ifelse(group == "Treatment", 
                     baseline_sbp - rnorm(100, 15, 5), 
                     baseline_sbp - rnorm(100, 5, 5))
)

# Calculating the change
trial_data <- trial_data %>% 
  mutate(sbp_change = final_sbp - baseline_sbp)

# The Analysis: ANCOVA (Analysis of Covariance)
# We control for baseline_sbp because patients start at different levels
model <- lm(final_sbp ~ baseline_sbp + group, data = trial_data)
tidy_results <- tidy(model)

print(tidy_results)

I prefer using lm() with the baseline as a covariate rather than just analyzing the "change score." Why? Because of "regression to the mean"—patients with extremely high baseline readings tend to drop more regardless of the drug. By including baseline_sbp in the model, we isolate the actual effect of Hypotens-X.

The Reality of Missing Data and ITT

In a perfect world, every patient finishes the trial. In the real world, people forget their pills or move away. In clinical trials, we use Intention-to-Treat (ITT) analysis. This means once you assign a patient to a group, they stay in that group for the analysis, even if they stopped taking the drug.

If you see NA values in your final_sbp column, you can't just use na.omit(). That's the "surviving plants" mistake I mentioned earlier. Depending on the protocol, you might use "Last Observation Carried Forward" (LOCF) or multiple imputation. For a simple analysis, we can use a basic imputation or a mixed-effects model that handles missingness more gracefully.

# A quick look at how we might handle a dropout using a simple mean imputation
# (Note: In a real trial, you'd use more complex methods like MICE)
trial_data_imputed <- trial_data %>%
  group_by(group) %>%
  mutate(final_sbp = if_else(is.na(final_sbp), mean(final_sbp, na.rm = TRUE), final_sbp))

Extracting the Clinically Meaningful Result

A p-value tells you if the drug worked, but the Confidence Interval (CI) tells you how much it worked. If the 95% CI for the blood pressure drop is [2mmHg, 4mmHg], it might be statistically significant, but is it clinically meaningful? Probably not. If it's [10mmHg, 20mmHg], now you've got a drug worth selling.

# Getting the confidence intervals for the treatment effect
confint(model, "groupTreatment", level = 0.95)

When you're reviewing these numbers, always check the sign. In our case, a negative coefficient for the treatment group is a "win" because we want blood pressure to go down.

📋 Practical Task

Analyzing the LDL-Cholesterol Reduction Trial

You have been handed a dataset from a 12-week trial of a new cholesterol-lowering agent. Your goal is to determine if the drug significantly reduced LDL cholesterol compared to a placebo, while controlling for the patient's starting LDL levels.

The Dataset: Create a dataframe called chol_trial with:

• patient_id: 1 to 60
• arm: Half "Drug", half "Placebo"
• ldl_start: Random values centered around 130 (sd = 20)
• ldl_end: For "Drug", subtract a random value between 20 and 40 from ldl_start. For "Placebo", subtract a random value between 0 and 10.

Your Requirements:

1. Build a linear model to test the effect of the arm on ldl_end, using ldl_start as a covariate.
2. Use the broom::tidy() function to extract the coefficients.
3. Calculate the 95% confidence interval for the armDrug coefficient.
4. Print a short sentence stating whether the drug is statistically significant (p < 0.05) and the estimated average reduction in LDL compared to placebo.